CYPH
Cypherpunk Technologies Inc. NASDAQ Listed Jan 25, 2017$1.06
Mkt Cap $60.1M
52w Low $0.23
23.9% of range
52w High $3.70
50d MA $0.78
200d MA $0.78
P/E (TTM)
13.3x
EV/EBITDA
-1.7x
P/B
0.4x
Debt/Equity
0.0x
ROE
3.1%
P/FCF
-1.7x
RSI (14)
—
ATR (14)
—
Beta
-0.22
50d MA
$0.78
200d MA
$0.78
Avg Volume
2.2M
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
47 Thorndike Street · Cambridge, MA 02141 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -0.07 | -0.23 | -246.4% | 0.70 | +0.7% | +12.6% | -9.7% | -1.3% | -0.4% | +1.2% | — |
| Nov 12, 2025 | AMC | -0.24 | -0.08 | +66.7% | 2.05 | -30.2% | -14.1% | +56.2% | -11.6% | +22.2% | -1.0% | — |
| Aug 14, 2025 | AMC | -0.29 | -0.40 | -37.9% | 0.24 | +4.3% | +10.1% | +7.6% | -0.7% | -6.3% | +2.5% | — |
| May 13, 2025 | AMC | -0.38 | -0.37 | +2.6% | 0.40 | -0.5% | +2.2% | +0.7% | -2.7% | +3.4% | -8.3% | — |
| Mar 26, 2025 | AMC | -0.39 | -0.37 | +5.1% | 0.45 | -9.6% | -19.6% | -13.2% | -3.6% | -4.5% | +16.7% | — |
| Nov 13, 2024 | AMC | -0.46 | -0.44 | +4.3% | 3.00 | +0.0% | -3.7% | -5.2% | +1.5% | -2.9% | -4.1% | — |
| Aug 12, 2024 | AMC | -0.42 | -0.52 | -23.8% | 2.38 | +2.5% | +8.4% | -4.7% | +0.0% | +1.2% | +2.4% | — |
| May 13, 2024 | AMC | -0.57 | -0.51 | +10.5% | 2.83 | +1.1% | -2.8% | +1.8% | -2.1% | -4.0% | -2.3% | — |
| Mar 18, 2024 | AMC | -0.56 | -0.46 | +17.9% | 2.14 | +1.4% | +2.8% | +15.9% | +0.0% | -1.2% | -4.8% | — |
| Nov 13, 2023 | AMC | -0.48 | -0.51 | -6.2% | 1.43 | +0.0% | +9.1% | +2.6% | -0.6% | +15.1% | +13.1% | — |
| Aug 14, 2023 | AMC | -0.98 | -0.91 | +7.1% | 2.40 | +1.7% | +5.8% | -8.3% | -5.2% | -2.7% | +2.3% | — |
| May 15, 2023 | AMC | -0.90 | -3.20 | -255.6% | 4.50 | +2.2% | +17.1% | +15.7% | +4.9% | +1.6% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | Baird | Maintains | Outperform → Outperform | — | $2.36 | $2.36 | +0.0% | +1.7% | +5.8% | -8.3% | -5.2% | -2.7% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.36 | +0.0% | +1.7% | +5.8% | -8.3% | -5.2% | -2.7% |
| Jul 12 | Raymond James | Maintains | Outperform → Outperform | — | $3.07 | $3.10 | +1.0% | +6.2% | +3.7% | -6.8% | -2.9% | -1.0% |
| Jun 22 | Raymond James | Maintains | Outperform → Outperform | — | $4.46 | $4.42 | -0.9% | -5.8% | -9.8% | -16.4% | -3.8% | +10.5% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.60 | +2.2% | +17.1% | +15.7% | +4.9% | +1.6% | +1.5% |
| Apr 13 | Mizuho | Maintains | Buy → Buy | — | $3.53 | $3.60 | +2.0% | +19.0% | -6.4% | -5.9% | +4.1% | -2.1% |
| Mar 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.18 | $3.12 | -1.9% | -8.8% | +6.9% | +5.5% | +0.3% | +3.7% |
| Mar 27 | Raymond James | Maintains | Outperform → Outperform | — | $3.18 | $3.12 | -1.9% | -8.8% | +6.9% | +5.5% | +0.3% | +3.7% |
| Mar 17 | Mizuho | Maintains | Buy → Buy | — | $4.38 | $3.70 | -15.5% | -16.9% | -3.8% | -3.7% | -0.6% | -1.5% |
| Jan 27 | Mizuho | Maintains | Buy → Buy | — | $6.70 | $7.00 | +4.5% | -4.3% | -1.7% | +5.6% | -2.3% | -1.2% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.97 | $5.19 | +4.4% | -2.2% | +10.9% | +33.4% | -9.2% | +1.1% |
| Nov 11 | Raymond James | Maintains | Outperform → Outperform | — | $6.20 | $6.35 | +2.4% | +1.0% | +12.6% | -0.6% | -5.1% | -9.6% |
| Aug 15 | Raymond James | Maintains | Outperform → Outperform | — | $12.90 | $13.40 | +3.9% | +10.9% | -2.8% | -7.2% | +2.3% | -4.5% |
| Jul 13 | Raymond James | Maintains | Outperform → Outperform | — | $11.40 | $11.60 | +1.8% | -0.9% | -2.7% | -0.9% | -0.9% | +4.6% |
| Oct 4 | Mizuho | Maintains | Buy → Buy | — | $36.50 | $37.48 | +2.7% | -1.9% | -2.0% | -7.4% | +3.4% | +0.3% |
| Sep 14 | Raymond James | Maintains | Outperform → Outperform | — | $17.70 | $17.50 | -1.1% | +1.1% | +7.8% | +31.1% | +4.7% | +4.5% |
| Mar 2 | Raymond James | Maintains | Outperform → Outperform | — | $24.30 | $25.00 | +2.9% | -3.7% | -1.3% | -11.7% | +5.4% | -6.0% |
| Aug 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.00 | $19.00 | +0.0% | +5.3% | -1.8% | -1.8% | -3.1% | -3.7% |
| Jun 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.90 | $22.50 | +2.7% | -0.5% | -4.1% | -3.3% | +2.5% | -3.9% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.40 | $23.10 | +3.1% | +2.7% | -2.2% | -4.4% | -0.9% | -6.6% |
| Mar 17 | H.C. Wainwright | Maintains | Buy → Buy | — | $13.00 | $13.80 | +6.2% | +9.2% | -17.6% | +12.8% | -3.8% | +3.1% |
| Feb 11 | Baird | Maintains | Outperform → Outperform | — | $18.60 | $20.40 | +9.7% | +14.5% | -4.2% | -1.5% | +7.0% | +7.0% |
| Jan 8 | Raymond James | Upgrade | Market Perform → Outperform | — | $16.80 | $16.00 | -4.8% | +4.8% | +10.8% | -5.6% | -7.6% | -1.8% |
| Nov 15 | Raymond James | Downgrade | Outperform → Market Perform | — | $6.27 | $6.10 | -2.7% | +2.7% | +13.0% | +4.7% | -5.0% | -4.7% |
| Dec 19 | Raymond James | Maintains | Outperform → Outperform | — | $27.10 | $26.40 | -2.6% | -0.7% | -6.7% | -6.0% | -3.4% | +1.3% |
| Apr 12 | H.C. Wainwright | Maintains | Buy → Buy | — | $97.10 | $98.10 | +1.0% | +3.1% | -2.7% | -23.1% | +1.1% | +1.2% |
| Mar 7 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $78.50 | $78.00 | -0.6% | +11.7% | +6.0% | -0.1% | -4.2% | -2.7% |
| Mar 1 | Raymond James | Maintains | Outperform → Outperform | — | $71.40 | $76.40 | +7.0% | +14.0% | -3.4% | -0.9% | +0.8% | +11.7% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Cypher Intelligence's executive change could signal leadership transition risks or strategic repositioning, potentially affecting investor confidence and operational continuity until replacement qualifications are disclosed.
Apr 10
8-K
Unknown — 8-K Filing
Cypherpunk Technologies released its 2025 full-year earnings results, providing investors with critical insight into revenue growth, profitability, and operational performance that will determine the stock's near-term valuation trajectory.
Mar 16
8-K
Cypherpunk Technologies Inc. -- 8-K Filing
Cypherpunk Technologies (CYPH) has 180 days to restore its stock price above Nasdaq's minimum bid requirement or face delisting, with a reverse stock split being a potential remedy.
Mar 9
Data updated apr 25, 2026 4:27am
· Source: massive.com